NGL Fine-Chem Limited (BOM:524774)

Market Cap	8.19B
Revenue (ttm)	3.68B
Net Income (ttm)	211.24M
Shares Out	6.18M
EPS (ttm)	34.19
PE Ratio	38.78
Forward PE	n/a
Dividend	1.75 (0.13%)
Ex-Dividend Date	Aug 12, 2025

Volume	287
Average Volume	198
Open	1,325.00
Previous Close	1,325.00
Day's Range	1,277.00 - 1,370.00
52-Week Range	962.70 - 2,774.40
Beta	0.66
RSI	79.28
Earnings Date	May 12, 2025

About NGL Fine-Chem

NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. The company offers animal health pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine hcl, s-methoprene, toltrazuril, decoquinate, amitraz, marbofloxacin, flunixin meglumine, praziquantel, carprofen, f...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1981
• Employees: 682
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524774

Financial Performance

In 2024, NGL Fine-Chem's revenue was 3.68 billion, an increase of 8.73% compared to the previous year's 3.39 billion. Earnings were 211.24 million, a decrease of -48.87%.